ArticleBMC cardiovascular disorders2026
Clinical relevance of the TAPSE/SPAP ratio in pulmonary arterial hypertension: a single-center retrospective study.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sex Differences in Echocardiographic Measures of Right Ventricular Function and RV-PA Coupling.Echocardiography (Mount Kisco, N.Y.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPulmonary arterial hypertension (PAH) is a life-threatening condition characterized by elevated pulmonary artery pressure and progressive right ventricular dysfunction. The ratio of tricuspid annular plane systolic excursion to systolic pulmonary artery pressure (TAPSE/SPAP) has been proposed as a noninvasive marker integrating right ventricular function and afterload. This study aimed to evaluate the clinical and prognostic relevance of TAPSE/SPAP in patients with PAH. METHODS AND
resultsThis study was a retrospective analysis of 125 patients newly diagnosed with PAH at the Xiangya Second Hospital between 2016 and 2022. The patients were divided into two groups based on the median TAPSE/SPAP ratio: a low TAPSE/SPAP group and a high TAPSE/SPAP group. The primary outcome was survival and follow-up was conducted until December 2023. The results showed that a lower TAPSE/SPAP ratio (< 0.15 mm/mmHg) was significantly associated with worse survival outcomes, with a higher mortality rate in the low TAPSE/SPAP group (17/63, 27%) than in the high group (7/62, 11.3%). The low TAPSE/SPAP group also exhibited more severe right ventricular remodeling and worse hemodynamic parameters. A significant inverse correlation was found between TAPSE/SPAP and both World Health Organization functional class and NT-proBNP levels, suggesting its role in noninvasive risk stratification.
conclusionIn this single-center retrospective cohort, a lower TAPSE/SPAP ratio was associated with more advanced disease and poorer outcomes in patients with PAH. Rather than serving as an independent prognostic predictor, TAPSE/SPAP may function as a composite, noninvasive marker reflecting right ventricular dysfunction and overall disease severity, and may be useful in clinical risk assessment when interpreted alongside established prognostic parameters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.